Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKinsey
McKesson
Medtronic
Merck

Last Updated: June 28, 2022

Custopharm Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Custopharm Inc
International Patents:1
US Patents:1
Tradenames:10
Ingredients:10
NDAs:10

Drugs and US Patents for Custopharm Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Custopharm Inc LEVOTHYROXINE SODIUM levothyroxine sodium SOLUTION;INTRAVENOUS 214253-001 May 17, 2021 RX Yes Yes 11,154,498 See Plans and Pricing Y See Plans and Pricing
Custopharm Inc FLUDARABINE PHOSPHATE fludarabine phosphate INJECTABLE;INJECTION 076349-001 Aug 28, 2003 AP RX No No See Plans and Pricing See Plans and Pricing
Custopharm Inc GANCICLOVIR SODIUM ganciclovir sodium INJECTABLE;INJECTION 212001-001 Jun 20, 2019 DISCN No No See Plans and Pricing See Plans and Pricing
Custopharm Inc DICYCLOMINE HYDROCHLORIDE dicyclomine hydrochloride INJECTABLE;INJECTION 210788-001 Feb 11, 2019 AP RX No No See Plans and Pricing See Plans and Pricing
Custopharm Inc ACETAMINOPHEN acetaminophen SOLUTION;INTRAVENOUS 202605-001 Jun 13, 2016 AP RX No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for CUSTOPHARM INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14

Supplementary Protection Certificates for Custopharm Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0957929 SPC/GB06/021 United Kingdom See Plans and Pricing PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
0480717 98C0022 France See Plans and Pricing PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
2822954 1890030-8 Sweden See Plans and Pricing PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625
2203431 92666 Luxembourg See Plans and Pricing PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
1758590 LUC00029 Luxembourg See Plans and Pricing PRODUCT NAME: SEL DE SODIUM D'ACIDE DEOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: IS/1/16/071/01 20170401
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Moodys
Express Scripts
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.